The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Technical report
Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease
Juan Luis Gutierrez-Chico, MD, PhD; Evelyn Regar, MD, PhD; Robert-Jan van Geuns, MD, PhD; Scot Garg, MD, PhD; Carl Schultz, MD, PhD; Nicolas van Mieghem, MD; Henricus Duckers, MD, PhD; Patrick W Serruys*, MD, PhD, FESC
Interventional Cardiology Department, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
Description
The Moxy drug-coated PTCA/PTA balloon (Lutonix, Inc. Maple Grove, MN, USA) is a paclitaxel-coated balloon with a hydrophilic carrier to optimize the drug release onto the vessel wall. It represents an interesting alternative to drug-eluting stent (DES) for the percutaneous treatment of in-stent restenosis, de novo coronary lesions or peripheral artery disease.
History
Adoption of DES has reduced coronary restenosis rates to 7.9-8.9% at nine months1-3, but this benefit is compromised by a higher incidence of late and very late stent thrombosis4-8. The polymer component of DES may contribute to inflammation of the ...
The Moxy drug-coated PTCA/PTA balloon (Lutonix, Inc. Maple Grove, MN, USA) is a paclitaxel-coated balloon with a hydrophilic carrier to optimize the drug release onto the vessel wall. It represents an interesting alternative to drug-eluting stent (DES) for the percutaneous treatment of in-stent restenosis, de novo coronary lesions or peripheral artery disease.
History
Adoption of DES has reduced coronary restenosis rates to 7.9-8.9% at nine months1-3, but this benefit is compromised by a higher incidence of late and very late stent thrombosis4-8. The polymer component of DES may contribute to inflammation of the ...
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next article
How should I treat a huge intra-mural haematoma of the ascending aorta after coronary angioplasty?
Latest news
NEW ISSUE
TAVI vs SAVR for bicuspid anatomies; PVR and TAVI; LAA thrombus trapping; crush techniques for bifurcation PCIs; stent elongation in POT and more
May 18, 2022
EUROPCR LATE BREAKING
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
FREE ARTICLE - Yair Feld et al
May 20, 2022
EUROPCR LATE BREAKING
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
FREE ARTICLE - Mattia Lunardi et al
May 18, 2022
EUROPCR LATE BREAKING
First dedicated transcatheter leaflet splitting device: the ShortCut device
FREE ARTICLE - Didier Tchétché et al
May 19, 2022
EUROPCR LATE BREAKING
Chordal replacement and annuloplasty in one device
FREE ARTICLE - Peter Skarsgard et al
May 19, 2022
EUROPCR LATE BREAKING
Implanting the first stent in the provisional pathway. The 16th expert consensus document of the EBC part 1
FREE ARTICLE - Remo Albiero et al
May 15, 2022
EUROPCR LATE BREAKING
Treatment of coronary bifurcation lesions, part II: implanting two stents. The 16th expert consensus document of the EBC
FREE ARTICLE - Jens Flensted Lassen et al
May 15, 2022